Company: ALX Therapeutics Inc.
Job title: Chief Medical Officer
ALX148 a Novel CD47 Myeloid Checkpoint Inhibitor in Patients with HNSCC 2:30 pm
CD47 is an anti-phagocytic SIRPα ligand often overexpressed by cancer cells to evade immune response correlates with poor clinical prognosis. The disruption of the CD47-SIRPα anti-phagocytic signal via CD47 blockade has been shown to maximize phagocytic activity against tumor cells in combination with a pro-phagocytic signal. Targeting the CD47-SIRPα myeloid checkpoint interaction with cancer therapeutics…Read more
day: Day One